- Email: [email protected]
Corrigendum to “Design, structure–activity relationship, and highly efficient asymmetric synthesis of 3-phenyl-4-benzylaminopiperidine derivatives as novel neurokinin-1 receptor antagonists” [Bioorg. Med. Chem. 19 (2011) 6430–6446]
Bioorganic & Medicinal Chemistry 22 (2014) 2379
Contents lists available at ScienceDirect
Bioorganic & Medicinal Chemistry journal homepage: www.elsevier.com/locate/bmc
Corrigendum
Corrigendum to ‘‘Design, structure–activity relationship, and highly efficient asymmetric synthesis of 3-phenyl-4-benzylaminopiperidine derivatives as novel neurokinin-1 receptor antagonists’’ [Bioorg. Med. Chem. 19 (2011) 6430–6446] Junya Shirai a,⇑, Takeshi Yoshikawa a, Masayuki Yamashita b, Yasuharu Yamamoto a, Makiko Kawamoto a, Naoki Tarui a, Izumi Kamo a, Tadatoshi Hashimoto a, Yoshinori Ikeura a a b
Pharmaceutical Research Division, Takeda Pharmaceutical Co. Ltd, 2-17-85, Jusohonmachi, Yodogawa-ku, Osaka 532-8686, Japan CMC Center, Takeda Pharmaceutical Co. Ltd, 2-17-85, Jusohonmachi, Yodogawa-ku, Osaka 532-8686, Japan
The starting compound 2 had been designed and synthesized for the biological activity by Mr. Yamaoka and Dr. Yukimasa although the compound was found as a HTS hit. However, the
DOI of original article: http://dx.doi.org/10.1016/j.bmc.2011.08.070
⇑ Corresponding author. Tel.: +81 6 6300 6673; fax: +81 6 6300 6306. E-mail address: [email protected] (J. Shirai). http://dx.doi.org/10.1016/j.bmc.2014.02.044 0968-0896/Ó 2014 Elsevier Ltd. All rights reserved.
achievement of them was not reflected in the original paper. Therefore, we would like to revise the description of the origin of the starting compound 2 and acknowledge them.
Contents lists available at ScienceDirect
Bioorganic & Medicinal Chemistry journal homepage: www.elsevier.com/locate/bmc
Corrigendum
Corrigendum to ‘‘Design, structure–activity relationship, and highly efficient asymmetric synthesis of 3-phenyl-4-benzylaminopiperidine derivatives as novel neurokinin-1 receptor antagonists’’ [Bioorg. Med. Chem. 19 (2011) 6430–6446] Junya Shirai a,⇑, Takeshi Yoshikawa a, Masayuki Yamashita b, Yasuharu Yamamoto a, Makiko Kawamoto a, Naoki Tarui a, Izumi Kamo a, Tadatoshi Hashimoto a, Yoshinori Ikeura a a b
Pharmaceutical Research Division, Takeda Pharmaceutical Co. Ltd, 2-17-85, Jusohonmachi, Yodogawa-ku, Osaka 532-8686, Japan CMC Center, Takeda Pharmaceutical Co. Ltd, 2-17-85, Jusohonmachi, Yodogawa-ku, Osaka 532-8686, Japan
The starting compound 2 had been designed and synthesized for the biological activity by Mr. Yamaoka and Dr. Yukimasa although the compound was found as a HTS hit. However, the
DOI of original article: http://dx.doi.org/10.1016/j.bmc.2011.08.070
⇑ Corresponding author. Tel.: +81 6 6300 6673; fax: +81 6 6300 6306. E-mail address: [email protected] (J. Shirai). http://dx.doi.org/10.1016/j.bmc.2014.02.044 0968-0896/Ó 2014 Elsevier Ltd. All rights reserved.
achievement of them was not reflected in the original paper. Therefore, we would like to revise the description of the origin of the starting compound 2 and acknowledge them.